Objectif Improvements in the characterization of human tumors have resulted in better survival rates for cancer patients. However, less progress has been made in the development of clinical tools to monitor the course of the disease. Tumor markers have not had a broad acceptance in the clinical community, because the few that are known are organ rather than tumor specific. Proteomics biomarker discovery research is usually a brute-force effort, and suffers from lack of reproducibility and high biological sample complexity. There is need for proteomics hypothesis-driven biomarker discovery approaches that incorporate technology advances with understanding cancer at the molecular level. I propose a biomarker discovery approach that combines exploiting the tumor cell’s communication with its microenvironment and with the rest of the organism, with a proteomics method designed to specifically measure secreted proteins (the ‘secretome’). My hypothesis is that signaling pathways are altered during tumorigenesis, and that these alterations are translated into protein differential secretion, which potentially can be used to discover secreted markers. The strategy proposed entails generating breast cancer secretome signatures and mine them to discover secreted pathway-based biomarkers. There is great hope that the discovery of pathway-based biomarkers in breast cancer secretomes will facilitate individualized diagnostics and treatment of breast cancer patients. Champ scientifique natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomicsmedical and health sciencesclinical medicineoncologybreast cancer Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) FP7-PEOPLE-2009-RG - Marie Curie Action: "Reintegration Grants" Appel à propositions FP7-PEOPLE-2009-RG Voir d’autres projets de cet appel Régime de financement MC-IRG - International Re-integration Grants (IRG) Coordinateur FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO) Contribution de l’UE € 100 000,00 Adresse CALLE NAZARET 115-117 08035 Barcelona Espagne Voir sur la carte Région Este Cataluña Barcelona Type d’activité Research Organisations Contact administratif Sandra Porta (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
